Clinical investigations which require a notification
Published:
Changes
Information regarding investigations of CE-marked medical devices that require a notification to NoMA.
Page contents
Which clinical investigations require a notification to NoMA?
Clinical investigations which fall under MDR Article 74 (1) require a notification to NoMA. These include clinical investigations to further assess a CE marked device within the scope of its intended use and where the investigation would involve submitting subjects to:
- procedures additional to those performed under normal conditions of use, and
- those additional procedures are invasive or burdensome.
Please consult the Q&A regarding clinical investigations for guidance on what is considered an invasive or burdensome procedure.
What needs to be submitted with the notification?
A notification of a clinical investigation must include the documentation listed below.
The requirements for the notification, including the content of the documents, are described in MDR Annex XV.
For a complete list of requirements that apply to these clinical investigations, please confer Article 74 (1).
We recommend using ISO 14155: 2020 "Clinical investigation of medical devices for human subjects - Good clinical practice" to understand the documentation requirements in MDR, and how to fulfil them.
Below you will find a description of the documents that are mandatory in the notification:
Overview of submitted documents for MDR notifications
Checklist with an overview of the submitted documents.
Application form
The application form (‘Application-Notification form’) must be filled in and signed. Attachment to part 3, 4 and 5 of the application form is used if necessary.
Instructions for use
Instructions for use of the device.
Confirmation that the device conforms to regulatory requirements
This is documented by submitting the Declaration of Conformity (DoC) of the device, and the EC certificate, if applicable.
Clinical investigation plan (CIP)
The CIP shall fulfil the requirements of MDR, Annex XV, Chapter II, Section 3 and preferably follow its layout with regards to subtitles.
The CIP shall also comply with the requirements of Annex A of ISO 14155:2020.
The reporting obligations that apply for substantial modifications (Art. 75), end or halt of the clinical investigation (Art. 77) and safety reporting (Art. 80(5) and (6)) must be clearly stated in the respective sections in the CIP. More information can be found on the websites Substantial modifications to clinical investigations, End or temporary halt of a clinical investigation and Safety reporting in clinical investigations.
An overall synopsis of the clinical investigation must be submitted in both Norwegian and English language, either as part of the CIP or as a separate document. The Norwegian and English version of the synopsis must be identical.
MDR Annex XV checklist
Checklist with an overview of the required information in CIP.
Confirmation on the suitability of the investigational site(s) and investigation team
The sponsor shall document that the principal investigator(s) and the investigational site(s) are suitable to conduct the clinical investigation in accordance with the Clinical Investigation Plan.
The competency of the principal investigator shall be documented by submitting his or her CV. This applies to the principal investigator at each investigation site.
Suitability of the investigation site shall be documented by a statement from the person in charge of the investigation site.
Proof of insurance cover of the subjects
Documentation indicating which patient injury insurance that covers the subjects of the clinical investigation.
The documentation shall confirm that any damage that may occur during the clinical investigation is covered by the insurance. It can be a copy of email correspondence with Norsk pasientskadeerstatning (NPE), or a copy of insurance certificates from an insurance company.
Patient information document and informed consent form
Template for the patient information document and informed consent form can be found on the Regional Committees for Medical and Health Research Ethics (REK) website.
Description of the protection and confidentiality of personal data
The following must be documented in the CIP or as a separate document, according to MDR Annex XV, Chapter II, Section 4.5:
- The organizational and technical measures that will be implemented to avoid unauthorized access, disclosure, dissemination, alteration or loss of information and personal data that is being processed.
- A description of measures that will be implemented to ensure confidential treatment of the subjects' records and personal data.
- A description of measures that will be implemented in the event of a breach of data security to limit possible negative effects.
Forms for notification
- Overview of submitted documents for MDR notifications (word)
- Clinical investigation - Application-Notification form (pdf)
- Appendix - Additional investigational device(s) (pdf)
- Appendix - Additional comparator device(s) (pdf)
- Appendix - Additional investigation site(s) (pdf)
- MDR Annex XV check list for CIP (word)
How to submit a notification?
Until EUDAMED is available the notification must be submitted by email to kki@noma.no. The subject heading should include "Clinical investigation notification", name of sponsor and name of device.
On the same day an application must be submitted to the Regional Committees for Medical and Health Research Ethics (REK) using the REK-portal. Required documents by REK are specified on their website. Documents submitted to both agencies must be identical.
When will I receive a decision?
The sponsor will receive a confirmation from NoMA that the notification has been received. The clinical investigation may commence 30 days after submission of the notification unless the sponsor is informed of otherwise.
It is a prerequisite that the Regional Committees for Medical and Health Research Ethics (REK) has not issued a negative opinion.
EU regulations on medical devices
Contact us
Unit for medical devices - development and notified body
Questions regarding clinical trials, classification and innovation guidance